Alector
$1.6350
42
-$0.18-9.67% Friday 20:00
Statistics
Day High
1.84
Day Low
1.625
52W High
3.32
52W Low
1.14
Volume
476,952
Avg. Volume
-
Mkt Cap
178.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.22375
Actual EPS
N/A
Financials
-118.39%Profit Margin
Unprofitable201.12MRevenue
-238.1MNet Income
Analyst Ratings
6.00Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALEC. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap28.94B
Anavex Life Sciences
AVXL
Mkt Cap280.8M
AC Immune SA
ACIU
Mkt Cap250.36M
Prothena
PRTA
Mkt Cap502.07M
Ionis Pharmaceuticals
IONS
Mkt Cap12.46B
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.32B
CRISPR Therapeutics
CRSP
Mkt Cap5.42B
Vertex Pharmaceuticals
VRTX
Mkt Cap113.59B
Novartis
NVS
Mkt Cap286.54B
About
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Arnon Rosenthal Ph.D.
Employees
175
Country
United States
ISIN
US0144421072
Listings
0 Comments
Share your thoughts
FAQ
What is Alector stock price today?▼
The current price of ALEC is $1.64 USD — it has decreased by -9.67% in the past 24 hours. Watch Alector stock price performance more closely on the chart.
What is Alector stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alector stocks are traded under the ticker ALEC.
Is Alector stock price growing?▼
ALEC stock has fallen by -24.31% compared to the previous week, the month change is a -36.38% fall, over the last year Alector has showed a +9.73% increase.
What is Alector market cap?▼
Today Alector has the market capitalization of 178.46M
When is the next Alector earnings date?▼
Alector is going to release the next earnings report on July 30, 2026.
What were Alector earnings last quarter?▼
ALEC earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.29 USD resulting in a +27.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alector revenue for the last year?▼
Alector revenue for the last year amounts to 201.12M USD.
What is Alector net income for the last year?▼
ALEC net income for the last year is -238.1M USD.
How many employees does Alector have?▼
As of June 06, 2026, the company has 175 employees.
In which sector is Alector located?▼
Alector operates in the Health & Wellness sector.
When did Alector complete a stock split?▼
Alector has not had any recent stock splits.
Where is Alector headquartered?▼
Alector is headquartered in South San Francisco, United States.